BioCentury on BioBusiness,
Product Discovery & Development
Eric Topol, J&J find potential use for CellSearch: predicting heart attacks
CellSearching the heart
Monday, April 16, 2012
Eight years after launching CellSearch to identify and count
circulating tumor cells, Johnson
& Johnson's Veridex LLC unit has new data showing the technology
may have the potential to predict heart attacks. Additional testing will be
required to figure out whether the findings can be developed into a test.
Veridex first launched
CellSearch in 2004 to identify and count circulating tumor epithelial cells
(CTCs) in blood samples from cancer patients. The in vitro diagnostic is
approved to predict progression-free survival (PFS) and overall survival (OS)
for patients with metastatic breast, colorectal and prostate cancers.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]